A Canadian Cancer Society-funded trial shows a 3-year structured exercise program post-chemotherapy improves survival for colon cancer patients. Involving 889 participants, the trial saw a 28% ...

The first-in-human results for pasritamig, a bispecific T-cell engager, show promising Phase 1 data in heavily pretreated ...

BioNTech and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...

The phase 3 SERENA-6 trial shows that ctDNA-guided early treatment switch to camizestrant plus a CDK4/6 inhibitor in HR+, ...

The new data from the Phase 3 C-POST trial presented at ASCO 2025 demonstrated that cemiplimab (Libtayo) reduced the risk of ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...

The new issue of ONCOLife, one of the leading oncology magazines for healthcare professionals, is now available — and it ...

Despite two decades of clinical experience with Everolimus in transplant medicine, cancer patients continue to face ...

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...

ONCOLife presents an exclusive interview with Sarah Hein, CEO of March Biosciences. In this session, we explore clinical ...